---
schema_version: "secwatch.filing_event.v1"
accession: "0001321732-25-000108"
form_type: "8-K"
ticker: "PEN"
cik: "0001321732"
company_name: "Penumbra Inc"
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:12:39.270202+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Penumbra Q3 revenue $354.7M (+17.8% YoY); full-year guidance raised to $1.375-1.380B

## Summary
- Net income of $45.9M; adjusted EBITDA $66.7M (18.8% margin).
- U.S. Thrombectomy revenue $192.0M (+18.5%); U.S. VTE revenue up 34% YoY.
- Gross margin improved to 67.8% vs 66.5% a year ago; operating margin 13.8%.
- Full-year 2025 revenue guidance increased to $1.375B-$1.380B (15-16% growth).
- Total revenue $354.7M (+17.8% or +16.9% constant currency); U.S. revenue +21.5%.

## SEC filing metadata
- accession: 0001321732-25-000108
- form_type: 8-K
- ticker: PEN
- cik: 0001321732
- company_name: Penumbra Inc
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321732/000132173225000108/0001321732-25-000108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321732/000132173225000108/pen-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001321732-25-000108
- JSON: https://secwatch.observer/filing/0001321732-25-000108.json
- Plain text: https://secwatch.observer/filing/0001321732-25-000108.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.